PCSK9-Inhibitoren

详细信息    查看全文

• 作者：Dr. A. Vogt
• 关键词：SchlüsselwörterLDL ; Cholesterin ; Hydroxymethylglutaryl ; CoA ; Reduktase ; Inhibitoren ; Hypercholesterinämie ; Lipoproteine ; Kardiovaskuläre Erkrankungen
• 刊名：Der Internist
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：58
• 期：2
• 页码：196-201
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Internal Medicine; General Practice / Family Medicine; Cardiology; Gastroenterology; Hepatology; Nephrology;
• 出版者：Springer Medizin
• ISSN：1432-1289
• 卷排序：58

文摘

BackgroundHypercholesterolemias are known risk factors for cardiovascular diseases. Although statins have reduced the cardiovascular morbidity and mortality and further therapeutic measures are available, treatment goals are often not achieved. In cases of very high levels of low-density lipoprotein (LDL) cholesterol or of intolerability, the established therapies are often not sufficiently effective or cannot be used in adequate doses. For these high-risk patients further treatment options are required.